# Prevention of HIV1 Mother to Child Transmission Without Nucleoside Analogue Reverse Transcriptase Inhibitors in the Pre-partum Phase. ANRS 135 Primeva

> **NCT00424814** · PHASE2,PHASE3 · COMPLETED · sponsor: **ANRS, Emerging Infectious Diseases** · enrollment: 105 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Kaletra (lopinavir/ritonavir)
- **DRUG:** Kaletra (lopinavir/ritonavir) + Combivir (zidovudine/lamivudine)

## Key facts

- **NCT ID:** NCT00424814
- **Lead sponsor:** ANRS, Emerging Infectious Diseases
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-03
- **Primary completion:** 2011-09
- **Final completion:** 2012-11
- **Target enrollment:** 105 (ACTUAL)
- **Last updated:** 2026-04-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00424814

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00424814, "Prevention of HIV1 Mother to Child Transmission Without Nucleoside Analogue Reverse Transcriptase Inhibitors in the Pre-partum Phase. ANRS 135 Primeva". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00424814. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*